Bioventus Inc. (NASDAQ:BVS) Receives Consensus Recommendation of "Buy" from Brokerages

Key Points

• Bioventus has a consensus “Buy” rating from six analysts: four buys, one hold and one strong buy. The average 12-month price target is $16.25, above the reported $14.13 opening price.
• The company’s latest quarterly results matched expectations, with adjusted EPS of $0.22 and revenue of $153.21 million. Management provided fiscal 2026 EPS guidance of $0.75–$0.79.
• Institutional investors hold 62.94% of Bioventus shares, with major firms including Nantahala Capital, Vanguard, Geode and Dimensional Fund Advisors recently increasing their positions.

Bioventus Inc. (NASDAQ:BVS - Get Free Report) has earned a consensus recommendation of "Buy" from the six research firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $16.25.

Several equities research analysts have recently issued reports on the company. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $15.00 target price on shares of Bioventus in a report on Tuesday, June 16th. Weiss Ratings raised Bioventus from a "hold (c)" rating to a "hold (c+)" rating in a research note on Thursday. Craig Hallum restated a "buy" rating and set a $18.00 price target on shares of Bioventus in a report on Thursday. Finally, Barrington Research set a $18.00 price objective on Bioventus in a research note on Thursday.

Bioventus Stock Performance

BVS opened at $14.13 on Friday. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.13 and a current ratio of 1.69. The stock has a market capitalization of $1.18 billion, a price-to-earnings ratio of 18.35, a PEG ratio of 1.80 and a beta of 0.63. The company has a fifty day moving average of $10.81 and a 200 day moving average of $9.69. Bioventus has a fifty-two week low of $6.26 and a fifty-two week high of $15.89.

Bioventus (NASDAQ:BVS - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $0.22 EPS for the quarter, hitting the consensus estimate of $0.22. Bioventus had a net margin of 9.36% and a return on equity of 28.08%. The business had revenue of $153.21 million for the quarter. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. As a group, sell-side analysts forecast that Bioventus will post 0.79 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Nantahala Capital Management LLC increased its position in Bioventus by 4.1% in the fourth quarter. Nantahala Capital Management LLC now owns 6,047,403 shares of the company's stock worth $44,993,000 after purchasing an additional 236,741 shares during the last quarter. Vanguard Group Inc. lifted its position in Bioventus by 4.4% during the third quarter. Vanguard Group Inc. now owns 2,924,788 shares of the company's stock valued at $19,567,000 after purchasing an additional 122,749 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Bioventus by 1.8% in the 4th quarter. Geode Capital Management LLC now owns 1,120,238 shares of the company's stock worth $8,337,000 after buying an additional 19,388 shares in the last quarter. State Street Corp grew its stake in shares of Bioventus by 1.7% in the 4th quarter. State Street Corp now owns 891,024 shares of the company's stock worth $6,629,000 after buying an additional 14,590 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Bioventus by 14.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 873,138 shares of the company's stock worth $7,971,000 after buying an additional 107,930 shares during the last quarter. 62.94% of the stock is owned by hedge funds and other institutional investors.

Bioventus Company Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source